Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago
Lexicon Pharmaceuticals (LXRX) announced four studies on sotagliflozin to be presented at the American Heart Association's Sessions 2024 in Chicago. A key secondary analysis of the Phase 3 SCORED trial showed sotagliflozin provided similar relative benefits across all heart failure stages, with increased absolute benefits in earlier stages. The presentations will cover the drug's cardioprotective effects, impact on systolic blood pressure in Type 2 diabetes patients, heart failure staging outcomes, and effects on myocardial contractile work.
Lexicon Pharmaceuticals (LXRX) ha annunciato quattro studi su sotagliflozin che saranno presentati durante le Sessioni 2024 dell'American Heart Association a Chicago. Un'analisi secondaria chiave dello studio di Fase 3 SCORED ha mostrato che sotagliflozin ha fornito benefici relativi simili in tutte le fasi di insufficienza cardiaca, con aumenti dei benefici assoluti nelle fasi più precoci. Le presentazioni copriranno gli effetti cardioprotettivi del farmaco, l'impatto sulla pressione arteriosa sistolica nei pazienti con diabete di tipo 2, i risultati della stadiazione dell'insufficienza cardiaca e gli effetti sul lavoro contrattile del miocardio.
Lexicon Pharmaceuticals (LXRX) anunció cuatro estudios sobre sotagliflozina que se presentarán en las Sesiones 2024 de la Asociación Americana del Corazón en Chicago. Un análisis secundario clave del ensayo de Fase 3 SCORED mostró que la sotagliflozina proporcionó beneficios relativos similares en todas las etapas de la insuficiencia cardíaca, con beneficios absolutos aumentados en las etapas más tempranas. Las presentaciones cubrirán los efectos cardioprotectores del medicamento, el impacto sobre la presión arterial sistólica en pacientes con diabetes tipo 2, los resultados de la estadificación de la insuficiencia cardíaca y los efectos sobre el trabajo contráctil del miocardio.
Lexicon Pharmaceuticals (LXRX)는 시카고에서 열리는 2024 미국 심장 학회 세션에서 발표할 소타글리플로진에 대한 네 가지 연구를 발표했습니다. 3상 SCORED 시험의 중요한 2차 분석에 따르면, 소타글리플로진은 모든 심부전 단계에서 유사한 상대적 이점을 제공했으며, 초기 단계에서 절대적 이점이 증가했습니다. 발표는 약물의 심장 보호 효과, 2형 당뇨병 환자의 수축기 혈압에 미치는 영향, 심부전 단계화 결과 및 심장 수축 작업에 미치는 영향을 다룰 것입니다.
Lexicon Pharmaceuticals (LXRX) a annoncé quatre études sur le sotagliflozine qui seront présentées lors des Sessions 2024 de l'American Heart Association à Chicago. Une analyse secondaire clé de l'essai de phase 3 SCORED a montré que le sotagliflozine offrait des avantages relatifs similaires dans toutes les étapes de l'insuffisance cardiaque, avec des avantages absolus accrus aux stades plus précoces. Les présentations couvriront les effets cardioprotecteurs du médicament, son impact sur la pression artérielle systolique chez les patients diabétiques de type 2, les résultats de la stadification de l'insuffisance cardiaque et les effets sur le travail contractile myocardique.
Lexicon Pharmaceuticals (LXRX) hat vier Studien zu Sotagliflozin angekündigt, die bei den Sessions 2024 der American Heart Association in Chicago vorgestellt werden. Eine wichtige sekundäre Analyse der Phase-3-Studie SCORED zeigte, dass Sotagliflozin in allen Stadien der Herzinsuffizienz ähnliche relative Vorteile bietet, mit erhöhten absoluten Vorteilen in den früheren Stadien. Die Präsentationen werden die kardioprotektiven Effekte des Medikaments, die Auswirkungen auf den systolischen Blutdruck bei Typ-2-Diabetes-Patienten, Ergebnisse der Stadieneinteilung der Herzinsuffizienz und die Auswirkungen auf die myokardiale Kontraktionsarbeit abdecken.
- Post-hoc analysis shows sotagliflozin benefits across all heart failure stages
- Drug demonstrates increased absolute benefits in earlier heart failure stages
- Multiple studies support drug's differentiation within SGLT inhibitor class
- None.
Insights
This post-hoc analysis presentation at AHA, while scientifically interesting, does not provide significant new actionable information for investors. The data presented is largely academic in nature, examining sotagliflozin's mechanism of action and effects across different heart failure populations. While it adds to the scientific understanding of the drug's differentiation within the SGLT inhibitor class, it doesn't materially impact the commercial prospects or regulatory status.
The four presentations focus on technical aspects like platelet activation, blood pressure effects and myocardial contractility. These incremental findings help build the scientific story but are unlikely to significantly influence prescriber behavior or market adoption in the near term. For investors, the key value drivers remain the drug's commercial performance and market penetration rather than these mechanistic studies.
Study results add to the growing body of evidence differentiating sotagliflozin within SGLT inhibitor class
THE WOODLANDS, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from four studies of sotagliflozin will be delivered during the American Heart Association’s (AHA) Sessions 2024 being held November 16-18 at McCormick Place Convention Center in Chicago, Illinois.
One of those studies, a secondary analysis of data from the Phase 3 SCORED clinical trial, examined the association of heart failure stage with cardiovascular disease and kidney events. Researchers in the study observed that sotagliflozin had similar relative benefits for all endpoints, irrespective of heart failure stage, with a corresponding increase in absolute benefits at earlier stages.
Details of the four presentations are as follows:
- “Sotagliflozin, a Dual Inhibitor of Sodium-Glucose Transporters 1 and 2, Elicits Cardioprotective Effects Through Attenuation of Platelet Activation and Thrombosis,” -- a poster presentation, Saturday, November 16, 4:17-4:27p.m. CT, Poster# 4134384, South Level 1, Area S104B, presented by Livia Stanger, Ph.D. candidate, University of Michigan, Ann Arbor, Michigan
- "Effect of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, on Systolic Blood Pressure in Patients with Type 2 Diabetes,” -- a poster presentation, Sunday, November 17. 11:30a.m.-12:30p.m., Poster# Su3019, Posters Zone 3, presented by M. Belinda Hardin, PharmD, US Medical Affairs, Lexicon Pharmaceuticals, Inc.
- “Association of the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients with Diabetes and Kidney Disease: A Secondary Analysis of the SCORED Trial,” -- a moderated poster presentation, Sunday, November 17, 3:15-3:20p.m CT, Poster# MDP1133, Posters Zone 4, presented by Ayodele Odutayo, Ph.D., M.D., University of Toronto, Ontario
- “Sotagliflozin Reduces Contractile Work In Human Living Myocardial Slices,” -- a poster presentation, Sunday, November 17, 3:15-4:15p.m. CT, Poster# Su1070, Poster Zone 1, South Level 3, Science & Technology Hall, presented by Rebecca Taichman, M.D. candidate, University of Pennsylvania, Philadelphia, Pennsylvania
“The post-hoc studies that will be presented at AHA reinforce our belief that sotagliflozin is differentiated within the SGLT inhibitor drug class. These studies help build a broad-based, scientific rationale supporting the dual mechanism of action of sotagliflozin,” said Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer.
About Sotagliflozin
Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1). SGLT2 is responsible for glucose and sodium reabsorption by the kidney and SGLT1 is responsible for glucose and sodium absorption in the gastrointestinal tract. Sotagliflozin has been studied in multiple patient populations encompassing heart failure, diabetes, and chronic kidney disease in clinical studies involving approximately 20,000 patients.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has commercially launched one of these medicines, INPEFA® (sotagliflozin) in the United States, and has a pipeline of other promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of sotagliflozin and its other drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
FAQ
What are the key findings from Lexicon's (LXRX) sotagliflozin SCORED trial analysis presented at AHA 2024?
How many studies on sotagliflozin will Lexicon (LXRX) present at AHA Sessions 2024?
What differentiates sotagliflozin from other SGLT inhibitors according to Lexicon's (LXRX) AHA 2024 presentations?
